Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

Carboplatin 205pembrolizumab 169Pemetrexed 144Cisplatin 126Paclitaxel 78durvalumab 75osimertinib 70Nivolumab 68Docetaxel 66Specimen Handling 64atezolizumab 60Magnetic Resonance Spectroscopy 54Etoposide 47Gemcitabine 46Radiotherapy 45Radiosurgery 40130-nm albumin-bound paclitaxel 36Drug Therapy 33Bevacizumab 29Cetuximab 28Ipilimumab 27cemiplimab 25Taxes 24tislelizumab 21Immunoglobulin G 21Radiation 20Platinum 20Biopsy 20amivantamab 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Toll-Like Receptor 1 × Thoracic × 90 days × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡